CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 10 enrolled
Drug / intervention
Nucaladrug
Likely dose
Nucala 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03494881
NCT03494881Early Ph 1Completed
CompareCT.gov

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria: An Open-label, Single-arm, Exploratory Study

Mayo Clinic·interventional·Posted Apr 11, 2018·Updated Aug 27, 2025

In Brief

A Early Phase 1 clinical trial evaluating Nucala for Chronic Spontaneous Urticaria. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This is an exploratory study designed to generate preliminary data in evaluating the efficacy of Nucala in the treatment of chronic spontaneous urticaria.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Spontaneous Urticaria
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedApr 11, 2018
Enrollment StartJul 30, 2019
Primary CompletionNov 15, 2023
Study CompletionFeb 25, 2025
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.2 years ago

Interventions

Nucaladrug

All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.